Gosset Breakpoint cluster region-Abelson murine leukemia viral oncogene 1 fusion protein Overview
The BCR-ABL1 fusion protein is a constitutively active tyrosine kinase generated by the t(9;22)(q34;q11) translocation, known as the Philadelphia chromosome[1][5][6][7]. Its unregulated kinase activity triggers a cascade of aberrant cellular signaling, including enhanced proliferation, impaired apoptosis, and altered cytoskeletal organization, which collectively drive malignant transformation in hematopoietic cells[1][3][4][5][6][7]. The protein contains functional domains derived from BCR (coiled-coil oligomerization and serine/threonine kinase regions) and ABL1 (SH2, SH3, tyrosine kinase, actin-binding domains)[1][3][4]. Targeted therapy with tyrosine kinase inhibitors (TKIs) has dramatically improved the treatment landscape for BCR-ABL1-positive leukemias but faces ongoing challenges related to drug resistance and adverse effects[1][3][5][7]. Detection of BCR-ABL1 transcripts is central for diagnosis, monitoring response to therapy, and risk stratification in patients with CML and related disorders[5].
Mechanism of Action
ATP-competitive inhibition of the kinase domain. Allosteric inhibition via non-ATP sites (asciminib). Blockage of tyrosine-autophosphorylation. Disruption of downstream oncogenic signaling (MAPK, PI3K/AKT, STAT pathways).
Biological Functions
Disease Associations
Safety Considerations
- TKI resistance (mutations in fusion protein, notably T315I)
- Off-target toxicities (myelosuppression, cardiovascular events)
- Drug interactions (CYP-mediated)
- Tumor lysis syndrome and cytopenias in aggressive leukemia states
Interacting Drugs
Associated Biomarkers
| Biomarker |
|---|
| BCR-ABL1 transcript quantification (PCR-based diagnostic/monitoring for CML) |
| Philadelphia chromosome detection (cytogenetics/FISH) |
| BCR-ABL1 kinase activity levels |